JP2004526412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004526412A5 JP2004526412A5 JP2002529483A JP2002529483A JP2004526412A5 JP 2004526412 A5 JP2004526412 A5 JP 2004526412A5 JP 2002529483 A JP2002529483 A JP 2002529483A JP 2002529483 A JP2002529483 A JP 2002529483A JP 2004526412 A5 JP2004526412 A5 JP 2004526412A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- polypeptide
- amino acid
- normal control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 210000001072 Colon Anatomy 0.000 claims description 59
- 229920001184 polypeptide Polymers 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 210000004072 Lung Anatomy 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 102000004965 antibodies Human genes 0.000 claims description 19
- 108090001123 antibodies Proteins 0.000 claims description 19
- 208000000409 Breast Neoplasms Diseases 0.000 claims description 16
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 201000001241 rectal neoplasm Diseases 0.000 claims description 8
- 108091006028 chimera Proteins 0.000 claims description 7
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 210000002307 Prostate Anatomy 0.000 claims description 4
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 3
- 102000018358 Immunoglobulins Human genes 0.000 claims description 2
- 108060003951 Immunoglobulins Proteins 0.000 claims description 2
- 210000004027 cells Anatomy 0.000 claims 17
- 230000035755 proliferation Effects 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 4
- 229920001405 Coding region Polymers 0.000 claims 3
- 210000002889 Endothelial Cells Anatomy 0.000 claims 2
- 210000004924 Lung microvascular endothelial cells Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000001737 promoting Effects 0.000 claims 2
- 102100007148 BDH2 Human genes 0.000 claims 1
- 101700020530 BDH2 Proteins 0.000 claims 1
- 210000001612 Chondrocytes Anatomy 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000006143 cell culture media Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 102100000509 SPCS3 Human genes 0.000 description 3
- 108060007808 SPCS3 Proteins 0.000 description 3
- 102100006930 UTS2 Human genes 0.000 description 2
- 101700025069 UTS2 Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 102100007614 GSG1L Human genes 0.000 description 1
- 101700022457 GSG1L Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22989600P | 2000-09-01 | 2000-09-01 | |
| US23062100P | 2000-09-05 | 2000-09-05 | |
| US23514700P | 2000-09-22 | 2000-09-22 | |
| PCT/US2000/030873 WO2001040465A2 (fr) | 1999-11-30 | 2000-11-10 | Compositions et procedes de traitement de maladies d'ordre immunologique |
| US26187801P | 2001-01-12 | 2001-01-12 | |
| US26191001P | 2001-01-16 | 2001-01-16 | |
| US26193901P | 2001-01-16 | 2001-01-16 | |
| US26215001P | 2001-01-16 | 2001-01-16 | |
| US26439501P | 2001-01-25 | 2001-01-25 | |
| US26642101P | 2001-02-02 | 2001-02-02 | |
| US26762301P | 2001-02-09 | 2001-02-09 | |
| PCT/US2001/006520 WO2001068848A2 (fr) | 2000-03-01 | 2001-02-28 | Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides |
| US27439901P | 2001-03-09 | 2001-03-09 | |
| US28098201P | 2001-04-03 | 2001-04-03 | |
| US28219901P | 2001-04-04 | 2001-04-04 | |
| US28212901P | 2001-04-04 | 2001-04-04 | |
| US29058901P | 2001-05-09 | 2001-05-09 | |
| PCT/US2001/017092 WO2001092331A2 (fr) | 2000-05-30 | 2001-05-25 | Compositions et methodes de traitement de maladies d'origine immune |
| PCT/US2001/017800 WO2001093983A1 (fr) | 2000-06-02 | 2001-06-01 | Polypeptides secretes et transmembranaires et acides nucleiques codant lesdits polypeptides |
| PCT/US2001/019692 WO2002000690A2 (fr) | 2000-06-23 | 2001-06-20 | Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese |
| PCT/US2001/021066 WO2002008288A2 (fr) | 2000-07-20 | 2001-06-29 | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
| PCT/US2001/021735 WO2002008284A2 (fr) | 2000-07-20 | 2001-07-09 | Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese |
| PCT/US2001/027099 WO2002024888A2 (fr) | 2000-09-01 | 2001-08-29 | Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006024604A Division JP2006223304A (ja) | 2000-09-01 | 2006-02-01 | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004526412A JP2004526412A (ja) | 2004-09-02 |
| JP2004526412A5 true JP2004526412A5 (fr) | 2010-01-28 |
| JP4451059B2 JP4451059B2 (ja) | 2010-04-14 |
Family
ID=27585542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002529483A Expired - Lifetime JP4451059B2 (ja) | 2000-09-01 | 2001-08-29 | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| JP2006024604A Pending JP2006223304A (ja) | 2000-09-01 | 2006-02-01 | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006024604A Pending JP2006223304A (ja) | 2000-09-01 | 2006-02-01 | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1341814A2 (fr) |
| JP (2) | JP4451059B2 (fr) |
| AU (2) | AU2002216610A1 (fr) |
| CA (2) | CA2632702A1 (fr) |
| WO (1) | WO2002024888A2 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP1133558B2 (fr) | 1998-11-27 | 2016-04-13 | UCB Pharma S.A. | Compositions et methodes d'augmentation de la mineralisation de la substance osseuse |
| EP1661997A1 (fr) * | 1999-12-01 | 2006-05-31 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
| JP2004520005A (ja) * | 2000-06-19 | 2004-07-08 | エフ．ホフマン−ラ ロシュ アーゲー | オステオレビン遺伝子多型性 |
| US7094570B2 (en) | 2003-03-11 | 2006-08-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| US7268223B2 (en) | 2000-09-22 | 2007-09-11 | Wyeth | Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof |
| NZ527087A (en) | 2001-01-12 | 2008-09-26 | Genetics Inst Llc | Type 2 cytokine receptor and nucleic acids encoding same |
| EP1406928B1 (fr) * | 2001-07-19 | 2010-04-14 | Innate Pharma | Ntb-a, une molecule de surface impliquee dans l'activite des cellules tueuses naturelles |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| FR2844713A1 (fr) * | 2002-09-25 | 2004-03-26 | Exonhit Therapeutics Sa | Nouvelle cible de l'angiogenese et utilisations |
| JP2006512923A (ja) * | 2002-10-18 | 2006-04-20 | エルジー ライフサイエンス リミテッド | 癌関連遺伝子ファミリー |
| ES2586401T3 (es) | 2003-06-16 | 2016-10-14 | Ucb Pharma S.A. | Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| EP2494362B1 (fr) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Marqueurs de tumeur de la prostate et méthodes d'utilisation |
| EP2494361B2 (fr) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation |
| EP2383578A1 (fr) * | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Marqueur de tumeur et procédés d'utilisation correspondants |
| PT3195880T (pt) | 2010-05-14 | 2020-02-21 | Amgen Inc | Formulações de anticorpos antiesclerostina de concentração elevada |
| MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
| KR20140018315A (ko) | 2011-03-25 | 2014-02-12 | 암젠 인크 | 항스클러로스틴 항체 결정 및 이의 제제 |
| DK2739311T3 (en) | 2011-08-04 | 2018-04-23 | Amgen Inc | Method of treating bone slit defects |
| KR20200056473A (ko) | 2011-12-28 | 2020-05-22 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
| EP2869844B2 (fr) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Traitement de maladies osseuses |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9708404B2 (en) | 2012-12-21 | 2017-07-18 | Seattle Genetics, Inc. | Anti-NTB-A antibodies and related compositions and methods |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| AU2019243595A1 (en) | 2018-03-30 | 2020-09-17 | Amgen Inc. | C-terminal antibody variants |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073454A1 (fr) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US5824504A (en) * | 1996-09-26 | 1998-10-20 | Elshourbagy; Nabil A. | Human 7-transmembrane receptor and DNA |
| CA2283299A1 (fr) * | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 nouvelles proteines secretees |
| EP0998490A2 (fr) * | 1997-03-25 | 2000-05-10 | Genetics Institute, Inc. | Proteines secretees et polynucleotides les codant |
| DE19817557A1 (de) * | 1998-04-09 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe |
| CA2328895A1 (fr) * | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Proteines membranaires et acides nucleiques codant ces proteines |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
-
2001
- 2001-08-29 CA CA002632702A patent/CA2632702A1/fr not_active Abandoned
- 2001-08-29 CA CA002421056A patent/CA2421056A1/fr not_active Abandoned
- 2001-08-29 JP JP2002529483A patent/JP4451059B2/ja not_active Expired - Lifetime
- 2001-08-29 EP EP01985272A patent/EP1341814A2/fr not_active Ceased
- 2001-08-29 AU AU2002216610A patent/AU2002216610A1/en not_active Abandoned
- 2001-08-29 WO PCT/US2001/027099 patent/WO2002024888A2/fr active Application Filing
- 2001-09-19 AU AU1661002A patent/AU1661002A/xx active Pending
-
2006
- 2006-02-01 JP JP2006024604A patent/JP2006223304A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004526412A5 (fr) | ||
| JP2006068016A5 (fr) | ||
| JP2006081548A5 (fr) | ||
| US20030119135A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030113853A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119121A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119119A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119124A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119126A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119122A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030175900A1 (en) | Compositions and methods for the treatment of tumor | |
| AU2002361467B2 (en) | Methods and compositions for pearl oyster cultivation | |
| US20030119138A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030170809A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| JP2004504061A (ja) | ＥｐｈＡ受容体ファミリーの新規メンバー | |
| US20030113856A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| CN104119448A (zh) | 含有富含亮氨酸重复序列的融合蛋白及其制法和应用 | |
| CN104119447A (zh) | 含有富含亮氨酸重复序列的融合蛋白及其制法和应用 | |
| US20030119120A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119114A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119141A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030113862A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119136A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030119116A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
| US20030138901A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same |